Please assess the completion status of the following clinical trial:

Trial Title: Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participant 18 to 80 years of age with Mixed Hyperlipidemia with LDL-C between 130 and 190 mg/dL and Triglycerides between 150 and 500 mg/dL~Exclusion Criteria:~* Pregnant or lactating women, or women intending to become pregnant~* Diabetes mellitus that is poorly controlled, newly diagnosed, or taking new or recently adjusted antidiabetic therapy (with the exception of ± 10 units of insulin)~* Human immunodeficiency virus (HIV) positive~* Any of the following within the past 3 months: heart attack, stoke, heart bypass surgery, unstable angina, angioplasty~* Active or chronic liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- MK-0524B 2g/20 mg (Type: EXPERIMENTAL): Co-administration of one tablet of MK-0524A (Extended Release \[ER\] niacin/laropiprant \[LRPT\] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks
- MK-0524B 2g/40mg (Type: EXPERIMENTAL): Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks
- Atorvastatin 10 mg (Type: ACTIVE_COMPARATOR): Atorvastatin 10 mg, orally, once daily for 12 weeks
- Atorvastatin 20 mg (Type: ACTIVE_COMPARATOR): Atorvastatin 20 mg, orally, once daily for 12 weeks
- Atorvastatin 40 mg (Type: ACTIVE_COMPARATOR): Atorvastatin 40 mg, orally, once daily for 12 weeks
- Atorvastatin 80 mg (Type: ACTIVE_COMPARATOR): Atorvastatin 80 mg, orally, once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).